Phase II Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
The purpose of this phase II trial is to study how well liposomal irinotecan, leucovorin, and fluorouracil work in treating patients with high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin that does not respond to treatment and has spread to other places in the body.
Study ID: I-64518
Trial Phase: Phase II
Trial Sponsor: Roswell Park Cancer Institute, Ipsen Biopharmaceuticals
Therapies Used in This Trial: Fluorouracil, Leucovorin, irinotecan liposome injection